At a glance
ClinicalIndex Comparison Record- ✓Diagnosis of acute lymphoblastic leukemia (ALL) of B- or T-cell lineage, or Philadelphia chromosome-positive ALL, or lymphoblastic lymphoma, or chronic myelogenous leukemia in lymphoid blast crisis
- ✓Age 18 years and over
- ✓Karnofsky performance status 20-100%
- ✓Left ventricular ejection fraction at least 50%
- ✕Prior biologic therapy
- ✕Prior chemotherapy
- ✕Prior endocrine therapy
- ✕Prior radiotherapy
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III Trial Comparing ARA-C/High-Dose Mitoxantrone ("ALL-2') to A Standard Vincristine/Prednisone Based Regimen ('L-20') as Induction Therapy For Adult Patients With Acute Lymphoblastic Leukemia (ALL): The ALL-4 Protocol
In Brief
A Phase 3 clinical trial evaluating dactinomycin, sargramostim, and 13 other interventions for Leukemia and Lymphoma. Completed, enrolled 170 participants across 7 sites.
Detailed Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which regimen of combination chemotherapy is more effective for acute lymphoblastic leukemia, lymphoblastic lymphoma, or chronic myelogenous leukemia. PURPOSE: This randomized phase III trial is studying two different chemotherapy regimens and comparing them to see how well they work in treating adults with acute lymphoblastic leukemia, lymphoblastic lymphoma, or chronic myelogenous leukemia.